Cancer drugs

From Libre Pathology
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

This article covers cancer drugs from a pathology perspective.

Drugs in a table

Non-proprietary name Trade name Cost Indication Notes
cetuximab Erbitux 5267 Euros/month[1] stomach cancer, head & neck cancer notes?
trastuzumab Herceptin 3345 Euros/month[1] breast cancer, stomach cancer notes?
gefitinib Iressa 3496 Euros/month[1] lung cancer EGFR inhibitor - like erlotinib
panitumumab Vectibix 3537 Euros/month[1] indication ??? notes?
fulvestrant Faslodex 719 Euros/month[1] breast cancer selective estrogen receptor down-regulator (SERD)
letrozole Femara 4189 Euros/month[1] indication ??? non-steroidal aromatase inhibitor
imatinib Gleevec/Glivec 4189 Euros/month[1] ALL, CML tyrosine kinase inhibitor
dasatinib Sprycel 7513 Euros/month[1] ALL, CML tyrosine kinase inhibitor
nilotinib Tasigna 5685 Euros/month[1] CML tyrosine kinase inhibitor
lapatinib Tyverb 3441 Euros/month[1] breast cancer tyrosine kinase inhibitor / HER2 growth receptor pathway blockade

See also

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Grill, Markus; Hackenbroch, Veronika (2011), "[Medizin: Das grosse Versprechen]", Der Spiegel (32): 124-128, 8.8.2011